# A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions

> **NCT06890286** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 53 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** BR3006
- **DRUG:** BR3006A
- **DRUG:** BR3006B
- **DRUG:** BR3006C

## Key facts

- **NCT ID:** NCT06890286
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-01
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-01-03
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06890286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06890286, "A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06890286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*